Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C

The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or...

Full description

Saved in:
Bibliographic Details
Published in:Revista de gastroenterología de México Vol. 67 Suppl 2; pp. S45 - S48
Main Author: Poo, Jorge Luis
Format: Journal Article
Language:Spanish
Published: Mexico 01-10-2002
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or 2b), or 24 weeks of treatment with IFN and ribavirin. Up to 60% of patients treated with standard IFN alpha and ribavirin are considered non-responders. According to viral genotype, figures are still worse in the group with genotype 1. Recently, the use of pegylated interferon allowed the reduction of the number of non-responding patients. The investigators propose different approaches in the search for better therapeutic strategies. The most effective of them all are the addition of ribavirin to the therapeutic scheme and the use of pegylated interferon which greatly increased the number of responders. Nevertheless, there are still many patients who are resistant to therapy. These are the proposed therapeutic alternatives for non-respondent patients: 1. Another tretment cycle with standard IFN and ribavirin (low probability) 2. Another treatment cycle with pegylated IFN and ribavirin. 3. Another treatment cycle with IFN, ribavirin and amantadine. 4. Another treatment cycle with IFN, ribavirin and timosine. 5. Other antiviral agents. It's important to clarify that "real non-responders" are those patients who remain positive in the viral load tests after 12-24 months of treatment. On the other hand, patients who "escape from treatment" or those with "recurrence" are not real non-responders, compared to those who are negative after 12-24 weeks of treatment.
AbstractList The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or 2b), or 24 weeks of treatment with IFN and ribavirin. Up to 60% of patients treated with standard IFN alpha and ribavirin are considered non-responders. According to viral genotype, figures are still worse in the group with genotype 1. Recently, the use of pegylated interferon allowed the reduction of the number of non-responding patients. The investigators propose different approaches in the search for better therapeutic strategies. The most effective of them all are the addition of ribavirin to the therapeutic scheme and the use of pegylated interferon which greatly increased the number of responders. Nevertheless, there are still many patients who are resistant to therapy. These are the proposed therapeutic alternatives for non-respondent patients: 1. Another tretment cycle with standard IFN and ribavirin (low probability) 2. Another treatment cycle with pegylated IFN and ribavirin. 3. Another treatment cycle with IFN, ribavirin and amantadine. 4. Another treatment cycle with IFN, ribavirin and timosine. 5. Other antiviral agents. It's important to clarify that "real non-responders" are those patients who remain positive in the viral load tests after 12-24 months of treatment. On the other hand, patients who "escape from treatment" or those with "recurrence" are not real non-responders, compared to those who are negative after 12-24 weeks of treatment.
Author Poo, Jorge Luis
Author_xml – sequence: 1
  givenname: Jorge Luis
  surname: Poo
  fullname: Poo, Jorge Luis
  email: jpoo@medicasur.org.mx
  organization: Dirección del Centro de Investigación Farmacológica y Biotecnología, Fundación Clínica Médica Sur. Puente de Piedra # 150, Col. Toriello Guerra, Deleg. Tlalpan. jpoo@medicasur.org.mx
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12712853$$D View this record in MEDLINE/PubMed
BookMark eNo9kE1LxDAYhHNYcT_0L0hO3gppsmmSoyx-wYKX3sub9q2NbJOapCz-eyuunmaYGZ7DbMnKB48rsmFCyYIZVq3JNqUPxlilGb8m65KrkmspNqSvI0Ie0WcaejpBdotN9OzyQCO2c4zoW6Qh0vMQaBeoD3kp0hR8R3OgeUDau5gyzf8geAfnl2TAH152iR5uyFUPp4S3F92R-umxPrwUx7fn18PDsZjkXhTG9GANSAEMjQC5L7W1wlqA1nYl00pqI5VlVWmqVgio0FrkolISVM94K3bk_hc7xfA5Y8rN6FKLpxN4DHNqFNd6rxVfhneX4WxH7JopuhHiV_N3jPgGH_VhfA
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Tratamiento de los pacientes con recaída o que no responden al primer tratamiento contra el virus de la hepatitis C
EndPage S48
ExternalDocumentID 12712853
Genre English Abstract
Journal Article
Review
GroupedDBID 0R~
0SF
457
65R
6I.
77H
AACTN
AAEDW
AAFTH
AALRI
AAXUO
ABMAC
ACGFS
ADBBV
ADCUG
ADEZE
ADVLN
AEVXI
AEXQZ
AFTJW
AGHFR
AITUG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BCNDV
CGR
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
FDB
FRP
GROUPED_DOAJ
GX1
IPNFZ
KQ8
NCXOZ
NPM
O9-
OK1
RIG
ROL
SSZ
W2D
7X8
ID FETCH-LOGICAL-p543-99fab9a53a0e93a5418bb3bbaacbd108758957b06196c33a6ebbe23675a7f02c3
ISSN 0375-0906
IngestDate Thu Apr 11 19:30:27 EDT 2024
Sat Sep 28 07:47:41 EDT 2024
IsPeerReviewed true
IsScholarly true
Language Spanish
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p543-99fab9a53a0e93a5418bb3bbaacbd108758957b06196c33a6ebbe23675a7f02c3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
PMID 12712853
PQID 72884872
PQPubID 23479
ParticipantIDs proquest_miscellaneous_72884872
pubmed_primary_12712853
PublicationCentury 2000
PublicationDate 2002-Oct
20021001
PublicationDateYYYYMMDD 2002-10-01
PublicationDate_xml – month: 10
  year: 2002
  text: 2002-Oct
PublicationDecade 2000
PublicationPlace Mexico
PublicationPlace_xml – name: Mexico
PublicationTitle Revista de gastroenterología de México
PublicationTitleAlternate Rev Gastroenterol Mex
PublicationYear 2002
SSID ssj0006802
Score 1.5663699
SecondaryResourceType review_article
Snippet The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage S45
SubjectTerms Antiviral Agents - therapeutic use
Hepatitis C - drug therapy
Humans
Interferons - therapeutic use
Recurrence
Ribavirin - therapeutic use
Title Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C
URI https://www.ncbi.nlm.nih.gov/pubmed/12712853
https://search.proquest.com/docview/72884872
Volume 67 Suppl 2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3Nb9MwFMAtugPigvhmbMA7cIsipXEc20e0dgLRjUODtFtkx87opZ6SVPDn8xy7aXdAwIGLFTlKIvkXPT-_T0I-tKywtrU85dIWPiUnS4XkNG3yhgnaGNxlxia2a359IxbLYnnozXeY-6-kcQ5Z-8zZf6A9vRQn8BqZ44jUcfw77lPkuI9lDlVTYwpb523roaqs65If311iXLJ1A97wgbJmr4e2G1QJj0PQb9UGtUhUKv37hk0fTav7ut4-QX1QibHJreqHzvkyn50XqqMXfjHeuQoe-Z_4403S2AWvjzfKJ6vd5r4FIp9i2abMK868vac8lqolT8a-pEl-JB7XoXRk3GnXocbm_SLY11_ry2-rVV0tb6oZmdG5j9NcfP4yba-lyIJrKH7090eDUUWonpDHUbeHjwHKU_LA9s_Iw6sYvfCctBMbcC3s2YBnAwc24DpANmAcIBuIbGBwgGxgZAMTG4hsYGIDFy9IdbmsLj6lsc9Fesd87INslZaKUZVZSRUr5kJrqrVSjTZz33FASMY1Kl6ybChVpdXa-sJ7TPE2yxv6kpxs3da-JsCbsigljpmkhdFWCdO0hSnxzKipteKUvN-vVY1ixPuG1Na6XV_zXAg8u-an5FVYwvouVDup5zlHHYbRN3989ow8Ovwe5-Rk6Hb2LZn1ZvduRPgLj51Llw
link.rule.ids 315,782,786
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+patients+with+recurrence+or+who+do+not+respond+to+the+first+treatment+against+hepatitis+C&rft.jtitle=Revista+de+gastroenterolog%C3%ADa+de+M%C3%A9xico&rft.au=Poo%2C+Jorge+Luis&rft.date=2002-10-01&rft.issn=0375-0906&rft.volume=67+Suppl+2&rft.spage=S45&rft.epage=S48&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0375-0906&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0375-0906&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0375-0906&client=summon